EpicentRx

About EpicentRx

EpicentRx™ is focused on achieving remission through the development of novel therapies targeting inflammatory diseases and supportive care conditions with unmet medical needs, emphasizing patient quality of life during treatment.

Products & Services

Nibrozetone (RRx-001):A Phase 3 investigational product from the PRETECT™ Platform, targeting inflammatory and supportive care unmet medical needs by inhibiting the inflammasome.

AdAPT (AdAPT-001):A lead clinical stage candidate from the AdAPT™ Platform, an immune checkpoint-stimulating anticancer immunotherapy.

eLoop Device:A proprietary device designed for optimized delivery of IV administered treatments.

Specialties

Inflammatory Disease Therapies Supportive Care Solutions Anticancer Immunotherapy Inflammasome Inhibition Oncolytic Viruses

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1599985 MR: - FA: $1.6 million FAN: 1599985	D: 2024-09-17 FD: 2024-09-17	1 investors

Grant Latest

2024-09-17

$1.6M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tony Reid

Chief Executive Officer

B

Bryan Oronsky

Chief Development Officer

F

Franck Brinkhaus

President & Chief Financial Officer

M

Meaghan Stirn

Vice President of Finance & Special Projects

C

Chris Larson

Vice President of Viral Therapy

S

Scott Caroen

Senior Director of Operations & Corporate Development

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

EpicentRx Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised